ResearchMoz

Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

GBI Research
Published Date » 2014-08-21
No. Of Pages » N/A
 GBI Research, the leading business intelligence provider, has released its latest research: ‘Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM’, which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products. The value of the GBM market in the APAC region amounted to an estimated $49.4m in 2013, and is expected to register a...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Introduction
2.1 Disease Introduction
2.2 Classification of Brain Tumors
2.3 Tumor Grading
2.4 Subtypes of Glioblastoma Multiforme
2.5 Etiology
2.6 Pathophysiology
2.6.1 Loss of Heterozygosity of Chromosome 10
2.6.2 Epidermal Growth Factor Receptor Amplification
2.6.3 Phosphatase and Tensin Homolog Mutation
2.6.4 Loss of p53 Function
2.6.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function
2.6.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation
2.7 Symptoms
2.8 Diagnosis
2.9 Prognosis
2.10 Epidemiology
2.11 Treatment Options
2.11.1 Surgery
2.11.2 Radiation Therapy
2.11.3 Chemotherapy
2.11.4 Targeted Therapy
2.11.5 Drugs for Symptom Relief
2.11.6 Other Alternative Therapies
2.12 Treatment Algorithm
2.13 GBI Research Report Guidance

3 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products
3.1 Key Marketed Products
3.2 Temodar (temozolomide) – Merck
3.3 Avastin (bevacizumab) – Roche
3.4 BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan)
3.4.1 BiCNU (carmustine) – Bristol-Myers Squibb
3.4.2 Gliadel Wafer (carmustine in polifeprosan) – Eisai
3.5 Unlicensed/Off-Label Use in Glioblastoma Multiforme
3.5.1 Lomustine
3.5.2 Carboplatin
3.5.3 Teniposide
3.6 Comparative Efficacy and Safety
3.7 Unmet Needs

4 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Pipeline
4.1 Overall Pipeline
4.2 Molecular Targets
4.3 Clinical Trials
4.3.1 Clinical Trial Size
4.3.2 Clinical Trial Duration
4.3.3 Failure Rate of Developmental Pipeline
4.3.4 Summary of Clinical Trial and Risk Analysis
4.4 Promising Pipeline Candidates
4.4.1 Rindopepimut (CDX-110) – Celldex Therapeutics
4.4.2 Avastin (bevacizumab) – Roche
4.4.3 Cotara – Peregrine Pharmaceuticals
4.4.4 BIOMAb (nimotuzumab) – BioCon
4.5 Heat Map of Safety and Efficacy and Product Competitiveness Framework for Glioblastoma Multiforme Pipeline

5 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Market Forecast to 2020
5.1 Asia-Pacific Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 Australia
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 India
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers for the Glioblastoma Multiforme Therapeutics in the Asia-Pacific Market to 2020
5.6.1 Drivers
5.6.2 Barriers

6 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Deals and Strategic Consolidations
6.1 Major Co-Development Deals
6.1.1 Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical
6.1.2 Immatics Biotechnologies Enters into Agreement with Cancer Research UK
6.2 Major Licensing Deals
6.2.1 Eisai Received Marketing Authorization Holder License with Nobelpharma for Gliadel in Japan
6.2.2 Teva Pharma Enters into Agreement with Perrigo for Generic Temozolomide
6.2.3 SOM Biotech Enters into Licensing Agreement with Argon Pharma for SOM0777
6.2.4 ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania
6.2.5 Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children’s Hospital Medical Center
6.2.6 Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center

7 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Bibliography
7.4 All Pipeline Products by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 Phase I
7.4.4 Phase II
7.4.5 Phase III and Pre-Registration
7.4.6 Undisclosed stage of development
7.5 Market Forecasts to 2020
7.5.1 Asia-Pacific
7.5.2 Australia
7.5.3 China
7.5.4 India
7.5.5 Japan
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Therapeutic Landscape
7.6.4 Forecasting
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Competitive Landscape
7.8 Expert Panel Validation
7.9 Contact Us
7.10 Disclaimer

List of Tables

Table 1: Glioblastoma Multiforme, Classification of Brain Tumors by the American Association of Neurological Surgeons, 2014
Table 2: Glioblastoma Multiforme, World Health Organization Classification of Glioma, 2005
Table 3: Glioblastoma Multiforme, Karnofsky Performance Status Score (%), 1984
Table 4: Discovery
Table 5: Preclinical and IND/CTA-filed
Table 6: Phase I
Table 7: Phase II
Table 8: Phase III and pre-registration
Table 9: Undisclosed stage of development
Table 10: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Forecast Data, 2013–2020
Table 11: Glioblastoma Multiforme Therapeutics, Australia, Forecast Data, 2013–2020
Table 12: Glioblastoma Multiforme Therapeutics, China, Forecast Data, 2013–2020
Table 13: Glioblastoma Multiforme Therapeutics, India, Forecast Data, 2013–2020
Table 14: Glioblastoma Multiforme Therapeutics, Japan, Forecast Data, 2013–2020

List of Figures

Figure 1: Glioblastoma Multiforme, Genetic Pathways to Primary and Secondary GBM and the Incidence of Mutations, 2014
Figure 2: Glioblastoma Multiforme, Treatment Algorithm for Glioblastoma Multiforme, 2014
Figure 3: Glioblastoma Multiforme, Treatment Options for Recurrent Glioblastoma Multiforme, 2014
Figure 4: Glioblastoma Multiforme, Global, Historical Sales of Temodar ($m), 2008–2013
Figure 5: Glioblastoma Multiforme, Global, Historical Sales of Avastin ($bn), 2004–2013
Figure 6: Glioblastoma Multiforme, Global, Historical Sales of Gliadel Wafer ($m), 2003–2006
Figure 7: Glioblastoma Multiforme , Global, Heat Map for Marketed Products, 2013
Figure 8: Glioblastoma Multiforme, Global, Overall Pipeline, 2013
Figure 9: Glioblastoma Multiforme, Global, Program Type by Phase and Molecular Targets, 2013
Figure 10: Glioblastoma Multiforme, Global, Mean Clinical Trial Size by Molecule Type, 2006–2013
Figure 11: Glioblastoma Multiforme, Global, Mean Clinical Trial Duration by Molecule Type (Months), 2006–2013
Figure 12: Glioblastoma Multiforme, Global, Clinical Trial Failure Rate by Phase by Molecule Type and Reasons for Failure, 2006–2013
Figure 13: Glioblastoma Multiforme, Asia-Pacific, Heat Map for Pipeline Products, 2013
Figure 14: Glioblastoma Multiforme, Asia-Pacific, Product Competitiveness Framework, 2013
Figure 15: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Treatment Use Patterns (‘000), 2013–2020
Figure 16: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Market Size ($m), 2013–2020
Figure 17: Glioblastoma Multiforme Therapeutics, Australia, Treatment Use Patterns (‘000), 2013–2020
Figure 18: Glioblastoma Multiforme Therapeutics, Australia, Annual Cost of Therapy ($), 2013–2020
Figure 19: Glioblastoma Multiforme Therapeutics, Australia, Market Size ($m), 2013–2020
Figure 20: Glioblastoma Multiforme Therapeutics, China, Treatment Use Patterns (‘000), 2013–2020
Figure 21: Glioblastoma Multiforme Therapeutics, China, Annual Cost of Therapy ($), 2013–2020
Figure 22: Glioblastoma Multiforme Therapeutics, China, Market Size ($m), 2013–2020
Figure 23: Glioblastoma Multiforme Therapeutics, India, Treatment Use Patterns (‘000), 2013–2020
Figure 24: Glioblastoma Multiforme Therapeutics, India, Annual Cost of Therapy ($), 2013–2020
Figure 25: Glioblastoma Multiforme Therapeutics, India, Market Size ($m), 2013–2020
Figure 26: Glioblastoma Multiforme Therapeutics, Japan, Treatment Use Patterns (‘000), 2013–2020
Figure 27: Glioblastoma Multiforme Therapeutics, Japan, Annual Cost of Therapy ($), 2013–2020
Figure 28: Glioblastoma Multiforme Therapeutics, Japan, Market Size ($m), 2013–2020

Upcoming Reports:

Poland: market of integrated circuits and electronic micromodules
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the integrated circuits and electronic micromodules market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the integrated circuits and electronic micromodules market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until...
Pancreatic Cancer Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecasts 2012 - 2018
By - Transparency Market Research
The global pancreatic cancer drug market is projected to reach USD 1.2 billion by 2015. Among all the regions, the United States has recorded the maximum number of pancreatic cancer cases, which are about 30,000 patients each year. The survival rate is less than 5 years which acts as a major hurdle for the growth of this market. The aggressive nature of pancreatic cancer and inadequate responses to the treatment acts as major obstacles in the treatment of such diseases. Moreover, pancreatic cancer is diagnosed when it is in its advanced stage, leading to increase in...
Poland: mead market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the mead market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the mead market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Pepsi Limon, A Brand New Addition to the Pepsi Portfolio
May 22, 2015  
To add a new dose of excitement to its cola offering, Pepsi has come up with the all new Pepsi Limon. This is a new flavored cola, which according to the company is manufactured with just the appropriate amount of real lime juice. The idea for the drink was inspired from the escalating preference of the Hispanic consumers. To satisfy the taste urges of the consumers, the new Pepsi Limon will...
India’s Auto Exports Register Record High Figures in 2014-15
May 21, 2015  
In the fiscal year 2014-15, Indian factories exported a record number of 3.5 million vehicles, which is 15% higher than what they managed a year back. However, domestic sales rose by only 5% since last financial year, with 2.6 million units being sold.  Exports of utility vehicles, commercial vehicles, cars and two- wheelers have increased every year since 2000. But domestic car...
Turkey’s Labor Dispute Affects Ford’s Production
May 21, 2015  
With the ongoing labor dispute in Turkey, Ford’s Turkish manufacturing facility has been hit. Ford Otosan, a joint venture between the company and Turkey’s Koc Holding, mentioned that due to supply problems, production has been temporary stalled at its plants located at Yenikoy and Golcuk in northwestern part of the country. Earlier this week, production at Tofas and Oyak Renault,...
International Automakers Slashing Prices in China
May 21, 2015  
With a slowing Chinese economy, the international automakers are cutting prices of vehicles to be sold in the nation. This has hit the profit margins of the automakers who are struggling with a slowdown in demand.  Last week saw Ford Motor Co. and General Motors slashing their prices on Chinese models. It closely follows rival Volkswagen AG’s move last month to offer...
Century Old Vancouver Sheet Metal Enterprise Shutters
May 21, 2015  
A Vancouver based metal works business in operation for almost 100 years, known for custom metal works shuttered this week.  The business known as Main Sheet Metal Works, a fabrication shop for sheet-metal on Main Street which is wedged between Pacific Central Station and Chinatown has existed for more than ninety years.  As commented by a third generation member of...